 NAPLES, Fla., April 1, 2021 PRNewswire -- Enveric Biosciences, Inc. NASDAQ: ENVB Enveric or the Company, a patient-first biotechnology company developing novel cannabinoid CBD_medicines to improve quality of life for cancer patients, today reported its financial results for the year ended December 31, 2020 and provided shareholders with an update on its accomplishments in 2021 thus far. 